Stocks · News reference
XOS: 140% | Xos shares are trading higher after the company announced that it has been awarded a prototype Other Transaction Agreement by the United States Air Force to develop and deliver a deployable mobile charging
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Amylyx Pharmaceuticals has surged 247% in 2026 following positive Phase 3 trial results for avexitide, its experimental treatment for post-bariatric hypoglycemia. With no current FDA-approved treatments for PBH and potential peak sales of $1.5 billion, the stock shows promise but may have already priced in much of the upside. The analyst suggests waiting for a pullback to $28-$30 per share for a better entry point.
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
Filed: 2026-08-20 AccNo: 0001193125-26-359418 Size: 411 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
America’s housing market is splitting along wealth lines.
A member of Congress recently unloaded over 20 stocks and continues a history of selling this year.